Catalyst
Slingshot members are tracking this event:
European Medicines Agency Accepts Bristol-Myers Squibb's (BMY) Type II Variation Application Seeking Expanded Approval for the Treatment of Adults With Advanced Renal Cell Carcinoma
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 05, 2015
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Type Ii Variation Application, Opdivo, Dvanced Renal Cell Carcinoma, Afinitor, Ema
